argenx (NASDAQ:ARGX) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of argenx (NASDAQ:ARGX) in a research report sent to investors on Monday, Benzinga reports. The firm currently has a $595.00 price target on the stock.

Other analysts have also issued research reports about the company. Scotiabank initiated coverage on argenx in a report on Monday, July 31st. They set a sector perform rating and a $516.00 price objective for the company. Piper Sandler upped their target price on argenx from $595.00 to $600.00 and gave the company an overweight rating in a research report on Thursday, August 31st. Societe Generale initiated coverage on argenx in a research report on Thursday, June 15th. They issued a sell rating on the stock. Stifel Nicolaus upped their target price on argenx from $478.00 to $601.00 in a research report on Monday, July 17th. Finally, Wells Fargo & Company upped their target price on argenx from $606.00 to $609.00 and gave the company an overweight rating in a research report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $522.73.

argenx Stock Down 0.9 %

argenx stock opened at $523.23 on Monday. The business has a fifty day moving average of $498.31 and a two-hundred day moving average of $424.43. The firm has a market cap of $30.63 billion, a P/E ratio of -72.97 and a beta of 0.75. argenx has a twelve month low of $333.07 and a twelve month high of $550.76.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, July 27th. The company reported ($1.69) EPS for the quarter, meeting the consensus estimate of ($1.69). argenx had a negative return on equity of 27.99% and a negative net margin of 47.28%. The firm had revenue of $281.16 million during the quarter, compared to analyst estimates of $258.32 million. During the same quarter in the prior year, the business posted ($3.81) EPS. Equities analysts expect that argenx will post -5.11 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CI Investments Inc. lifted its stake in argenx by 202.6% in the 4th quarter. CI Investments Inc. now owns 79 shares of the company’s stock valued at $30,000 after buying an additional 156 shares in the last quarter. KB Financial Partners LLC lifted its stake in argenx by 112.5% in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares in the last quarter. Nkcfo LLC purchased a new position in argenx in the 2nd quarter worth approximately $37,000. Toronto Dominion Bank purchased a new position in argenx in the 1st quarter worth approximately $36,000. Finally, Captrust Financial Advisors lifted its stake in argenx by 116.7% in the 1st quarter. Captrust Financial Advisors now owns 143 shares of the company’s stock worth $45,000 after purchasing an additional 77 shares in the last quarter. 52.77% of the stock is owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.